NPO Microgen, a part of Nacimbio holding company, completed the clinical trials to expand the indications for use of Relatox, a botulinum toxin type A.
The results of trials confirmed its therapeutic efficacy in the treatment of axillary hyperhidrosis, the excessive armpit sweating. Earlier, the drug has successfully passed all clinical trials phases for the treatment of spastic forms of cerebral palsy in patients aged 13 to 17 years old. The drug acts by blocking the transmission of nerve impulses to sweat glands, which leads to termination of their secretory function.
According to the survey conducted among the participants in phase III clinical trials on expanding the indications for use of Relatox, more than 95% of patients reported the high efficacy of the drug, improvement in their quality of life, and expressed willingness to repeat the treatment.
“The drug can compete with its foreign analogs in a number of areas on the Russian market. The registration of expanded indications for its use should be completed in Q2 this year. This will be yet another step in the development of Russian pharmaceutical industry in the area of cosmetology and neurology,” said Kirill Gaidash, the General Director of NPO Microgen.
Relatox, a botulinum toxin with new expanded indications, will become available on the market in 2018.